Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform
Journal of Medicinal Chemistry2011Vol. 54(22), pp. 7815–7833
Citations Over TimeTop 11% of 2011 papers
Timothy P. Heffron, BinQing Wei, Alan G. Olivero, Steven T. Staben, Vickie Tsui, Steven Do, Jennafer Dotson, Adrian Folkes, Paul Goldsmith, Richard Goldsmith, Janet L. Gunzner, John Lesnick, Cristina Lewis, Simon Mathieu, Jim Nonomiya, Stephen Shuttleworth, Daniel P. Sutherlin, Nan Chi Wan, Shumei Wang, Christian Wiesmann, Bing‐Yan Zhu
Abstract
Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chemical series. In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3Kα that is not attained with the corresponding Lys777 of PI3Kβ. In the benzoxepin series of inhibitors, the selectivity observed can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.
Related Papers
- → Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues(2009)39 cited
- → Functional Roles of the α Isoforms of the Na,K‐ATPase(2003)98 cited
- → Relative expression of TAp73 and ΔNp73 isoforms(2012)32 cited
- → Tissue specific expression of Myosin IC Isoforms(2014)21 cited
- → Physiological Role of Na,K‐ATPase Isoforms(2004)